Topics:

Oncology and Hematology News and Journal Articles

FDA Approves Ramucirumab for Second-Line Treatment of mCRC

The FDA has approved ramucirumab, a human VEGFR2 antagonist in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer.

Recent Content

Preoperative albumin level and number of extended cytoreductive procedures in ovarian cancer patients predicted the likelihood of surgical complications.

Pancreatic neuroendocrine neoplasm (somatostatinoma)

This slide show features various magnifications of pancreatic neuroendocrine tumors (PNETs) displaying granular cell-like, clear cell, and other features.

The CONCUR trial found that regorafenib improved overall survival in a large group of Asian patients with treatment-refractory metastatic colorectal cancer.

A new study suggests that a family history of breast cancer does not result in a worse prognosis breast cancer prognosis.

The Federal Trade Commission has charged four US cancer charities with fraud, accusing them of diverting more than $187 million in charitable donations.

Patients with acute myeloid leukemia who had a DNMT3A mutation had poorer disease prognosis, according to an analysis of patients aged 60 years or younger.

A prospective study found that a bronchial airway gene-expression classifier improved the diagnostic performance of bronchoscopy for lung cancer detection.

By clicking Accept, you agree to become a member of the UBM Medica Community.